Baseline characteristics
| Characteristic . | Patients (N = 129) . |
|---|---|
| Median age at baseline (range, IQR), y | 23 (9-55, 18-33) |
| Median age at follow-up (range, IQR), y | 34 (12-67; 28-45) |
| Sex, n (%) | |
| Male | 59 (45.7) |
| Female | 70 (54.3) |
| Hb genotype, n (%) | |
| HbSS | 62 (48.1) |
| HbSβ0 | 8 (6.2) |
| HbSβ+ | 13 (10.1) |
| HbSC | 46 (35.7) |
| Median follow-up (IQR), y | 11 (8.5-12) |
| Hydroxyurea use, n (%) | 28 (21.7) |
| Chronic transfusion therapy, n (%) | 9 (7.0) |
| Mean HbF (± standard deviation), % | |
| Patients with HbSS/HbSβ0/HbSβ+ | 7.5 (± 6.1) |
| Patients with HbSC | 1.8 (± 1.3) |
| Characteristic . | Patients (N = 129) . |
|---|---|
| Median age at baseline (range, IQR), y | 23 (9-55, 18-33) |
| Median age at follow-up (range, IQR), y | 34 (12-67; 28-45) |
| Sex, n (%) | |
| Male | 59 (45.7) |
| Female | 70 (54.3) |
| Hb genotype, n (%) | |
| HbSS | 62 (48.1) |
| HbSβ0 | 8 (6.2) |
| HbSβ+ | 13 (10.1) |
| HbSC | 46 (35.7) |
| Median follow-up (IQR), y | 11 (8.5-12) |
| Hydroxyurea use, n (%) | 28 (21.7) |
| Chronic transfusion therapy, n (%) | 9 (7.0) |
| Mean HbF (± standard deviation), % | |
| Patients with HbSS/HbSβ0/HbSβ+ | 7.5 (± 6.1) |
| Patients with HbSC | 1.8 (± 1.3) |